Featured

Prediction of Progression in Barrett’s Esophagus Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter Studies

Iyer PG, Codipilly DC, Chandar AK, Agarwal S, Wang KK, Leggett CL, Latuche LR, Schulte PJ

Clinical Gastroenterolgy and Hepatology 2022

View

An Objective, Fully Automated Barrett’s Risk Prediction Assay Outperforms Pathology in Risk Stratifying Barrett’s Esophagus with Low-Grade Dysplasia

A.M. Khoshiwal, N.F. Frei, L.C. Duits, R.E. Pouw, Barrett’s SURF LGD Study Pathologist Consortium, E. Bossart, M. Wilhelm, R. Critchley-Thorne, J.J. Bergman

Adapted from a DDW 2022 Podium Presentation

View

Bibliography

View Printable Bibliography

How TissueCypher Is Referenced in Publications

In most peer reviewed publications, a non-proprietary and non-branded product name is required for article acceptance. Below is a listing of names that have been used to generically describe TissueCypher, without referring to it by its brand name:

  • Tissue Systems Pathology Test
  • Risk Prediction Test
  • Risk Prediction Assay
  • Risk Prediction Multi-Biomarker Assay